Washington, DC (April 28, 2025) – As the Senate Committee on Appropriations prepares to hold a hearing on biomedical research funding on April 30, UsAgainstAlzheimer’s is calling on lawmakers to safeguard and strengthen federal investment in biomedical research—especially in the fight against Alzheimer’s and other dementias.

“We commend the Senate Appropriations Committee for shining a vital spotlight on the importance of our nation’s pathway to cures,” said George Vradenburg, Chairman and Co-Founder of UsAgainstAlzheimer’s. “Investing in health has always been a bipartisan priority. There are no Republican or Democratic diseases or illnesses. The bipartisan attention to this issue underscores a shared understanding of its profound impact on the lives of millions, including those battling Alzheimer’s. This commitment offers a beacon of hope for continued progress.”

UsAgainstAlzheimer’s cautioned against proposals that would drastically reduce funding for essential health agencies like the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA). “We must be clear: disorganized and significant cuts to these vital research engines would be incredibly dangerous,” Vradenburg emphasized. “Such actions would jeopardize the remarkable advancements made possible by sustained federal investment over the past decade in the fight against Alzheimer’s and countless other diseases. Slashing funding without a strategic and transparent approach will delay crucial breakthroughs and hurt countless individuals and families.”   

Looking ahead, UsAgainstAlzheimer’s urges Congress to adopt a sustained and strategic funding approach, including strong support for biomedical research through the NIH, FDA, and CDC.  Long-term, consistent investment is necessary for producing innovative treatments, expanding access to clinical trials, supporting prevention and building a modernized brain health infrastructure.